Serum MIF in Acute Kidney Injury

Medical University of Vienna500 enrolled

Overview

Acute kidney injury (AKI) is a common complication in critical care patients. Currently no parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate the time course of MIF concentrations in patients with AKI.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Acute Kidney Injury

Interventions

Blood draw for measurement of MIFOTHER

Observational study, no intervention

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Exclusion Criteria: * Age \< 18 years and \> 80 years * Patients with chronic dialysis * Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4 weeks prior to the study * Patients with an expected length of ICU stay shorter than 3 days * Patients with a low probability of surviving the first 2 days after ICU admission * Pregnancy and nursing

Locations (1)

Medical University of Vienna

Vienna, Austria

Outcomes

Primary Outcomes

Macrophage migration inhibitory factor

Time frame: Up to 14 days

Secondary Outcomes

Serum creatinine

Time frame: Up to 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.